2022
DOI: 10.3390/biom12091301
|View full text |Cite
|
Sign up to set email alerts
|

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Abstract: Metformin and statin use have been associated with an improved prognosis for colorectal cancer in persons with type 2 diabetes (T2D). Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design. We identified 1271 eligible patients with T2D and incident RC between 1998 and 2011 from the Diabetes in Finland (FinDM) database. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard rati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
4
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(4 citation statements)
references
References 51 publications
0
4
0
Order By: Relevance
“…32 On the other hand, Erkinantti did not find any different in OS or DFS between metformin users, patients on other anti-diabetics, or patients on no anti-diabetic medications. 31 Hence, we evaluated the role of metformin in Locally Advanced Rectal Cancer (LARC) treated with neoadjuvant therapy and resection at our institution.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…32 On the other hand, Erkinantti did not find any different in OS or DFS between metformin users, patients on other anti-diabetics, or patients on no anti-diabetic medications. 31 Hence, we evaluated the role of metformin in Locally Advanced Rectal Cancer (LARC) treated with neoadjuvant therapy and resection at our institution.…”
Section: Discussionmentioning
confidence: 99%
“…The current literature on the effect of DM on the prognosis of rectal cancer remains debatable. 14,15,31,33 The conflicting results of the effect of metformin in population-based studies can be explained at least in part, due to the heterogeneity in study designs (observational/ trials with variable regimens/systematic reviews and meta-analyses) and comparison groups (diabetic metformin users/diabetic non-metformin users/non-diabetics). Further, observational studies studying drug effects tend to be susceptible to time-related biases such as immortal-time bias (misclassification or ignorance of variation in the timing of treatment initiation from cohort entry), time-window bias (cases and controls not matched on the duration of exposure opportunity time within a fixed observation period), and time-lagging bias (when a first-line therapy is compared to the second-or third-line of therapy given at a different disease stage) resulting in potential overestimation of a drug effect when there is none.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations